MMV-supported projects

**Research**
- Lead optimization
  - Pyrazines GSK
  - Phenotypic Lead Mitsubishi Tanabe
  - Intra-muscular Caster
  - Phenotypic Lead BMS
  - GWT1 Eli Lilly
  - Molecular Target DOG Dundee
  - Azbenzimidazoles UNCAMP

- Candidate profiling
  - Miniportfolio Novartis
  - MMV1581373 Novartis
  - MMV1793609 Kyorin
  - MMV646 Jacobs
  - DHODH Broad
  - DHODH UTSW/ UWA/ Monash
  - Phenotypic Lead Merck KgaA-UCT
  - Azbenzimidazoles UNCAMP

**Translational**
- Preclinical
  - MMV370 Janssen
  - MMV183 TropiQ
  - MMV646 Jacobs
  - MMV253 Synta Caddia
  - Atosiban BMS
  - MMV533 Sanofi

- Human volunteers
  - P215 Janssen
  - M5717 Merck KgaA
  - Cipargamin Novartis
  - MMV048 UCB
  - MMV533 Sanofi

**Product development**
- Patient exploratory
  - Ferroquine / Artefenomel Sanofi
  - Ganapadile / Lumefantrine GSK
  - Cipargamin Novartis
  - Sulfadoxine / Pyrimethamine Universal Corporation
  - Sulfadoxine-pyrimethamine Swephta/Bogaran

- Patient confirmatory
  - Dihydroartemisinin-piperaquine dispersible Ateliers
  - Tafenoquine paediatric GSK
  - Dihydroartemisinin-piperaquine dispersible Ateliers
  - Sulfadoxine-pyrimethamine Swephta/Bogaran
  - Artemether-lumefantrine <5kg Novartis

**Regulatory review**
- Approved/ERP
  - Artemether-lumefantrine dispersible Novartis
  - Dihydroartemisinin-piperaquine dispersible Fouson Pharma
  - Sulfadoxine-pyrimethamine dispersible Fouson Pharma
  - Sulfadoxine-pyrimethamine dispersible Fouson Pharma
  - Artesunate for injection Fouson Pharma
  - Artesunate for injection Ipca
  - Dihydroartemisinin-piperaquine Artzigma
  - Pyronaridine-artesunate Shionogi
  - Pyronaridine-artesunate Shionogi
  - Tafenoquine GSK

**Access**
- MMV support to projects may include financial, in-kind, and advisory activities.

Footnotes: 
1: Included in MMV portfolio after product approval and/or development. 
2: DNDi and partners completed development and registration of ASMQ and ASAQ. 
3: Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. 
4: WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers. 
5: paediatric formulation. 
6: via bioequivalence study. Past partners are in brackets (-).

Brand names: 1: Coartem® Dispersible; 2: Artesun®; 3: Larinate® 60mg; 4: Eurartesim®; 5: Pyramax® tablets or granules; 6: ASAQ Winthrop®; 7: SPAQ-GOT™; 8: Suprya® 
9: 100mg Artesunate RectoCaps; 10: Artescap™; 11: Kzenis/Krintafel (Trademarks owned or licensed by GSK)

September 2020
Footnotes: MMV-supported projects

Target Product Profiles and Target Candidate Profiles

MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign.


<table>
<thead>
<tr>
<th>Target Product Profiles</th>
<th>Target Candidate Profiles</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-day cure, artemisinin-based combination therapies (TPP-1)</td>
<td>Asexual blood stages Burrows et al., 2013 (TCP-1,2) Burrows et al., 2017 TCP-1</td>
</tr>
<tr>
<td>Uncomplicated malaria treatments for single-exposure radical cure (SERC) and/or resistance management (TPP-1)</td>
<td>Relapse prevention (TCP-3a) TCP-3</td>
</tr>
<tr>
<td>Severe malaria treatment / pre-referral intervention (TPP-1)</td>
<td>Transmission reduction (TCP-3b) TCP-5,6</td>
</tr>
<tr>
<td>Intermittent preventive treatment (TPP-1)</td>
<td>Causal prophylaxis (TCP-4) TCP-4</td>
</tr>
<tr>
<td>Products targeting prevention of relapse for P. vivax (TPP-1)</td>
<td></td>
</tr>
<tr>
<td>Prophylaxis (TPP-2)</td>
<td></td>
</tr>
</tbody>
</table>